Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Sanofi India Ltd. Share Price
Day's Range
Day's Range
Low
₹3,398.70
High
₹3,438.00
Price Summary
| Previous Close | ₹3,435.50 |
|---|---|
| Day's Range | ₹3,398.70 - ₹3,438.00 |
| Open | ₹3,419.00 |
| 52 Week Range | ₹3,160.00 - ₹6,410.00 |
| Volume | 9,749 |
| Market Cap | ₹0.01 |
| Previous Close | ₹3,439.60 |
|---|---|
| Day's Range | ₹3,397.40 - ₹3,439.60 |
| Open | ₹3,419.80 |
| 52 Week Range | ₹3,151.05 - ₹6,399.95 |
| Volume | 723 |
| Market Cap | ₹0.01 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 334.93 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 3.62 |
| Price/Earning (TTM) | 18.93 |
| TTM EPS (₹) | 179.46 |
| P/E Ratio | 34.06 |
| Book Value(₹) | 9.89 |
| PAT Margin (%) | 15.20 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 46.16 |
| Trade Value ( ₹ in Lacs) | 24.87 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 3.62 |
| Price/Earning (TTM) | 18.93 |
| TTM EPS (₹) | 179.46 |
| P/E Ratio | 34.06 |
| Book Value(₹) | 9.89 |
| PAT Margin (%) | 15.20 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 46.16 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 5359.0 | 20132.0 |
| Expenses | N/A | N/A |
| PBT | 1653.0 | 4314.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 1195.0 | 4135.0 |
About Sanofi India Ltd.
| Founded | 1956 |
|---|---|
| Managing Director | Deepak Arora |
| NSE Symbol | SANOFI |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,43,972.94 | 1,840.90 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,78,025.88 | 6,733.15 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,47,477.60 | 4,350.20 | 3,101.60 - 3,101.60 |
| Lupin Ltd. | 1,11,668.12 | 2,470.00 | 1,836.80 - 1,836.80 |
| Apollo Hospitals Enterprise Ltd. | 1,11,526.57 | 7,830.00 | 6,677.50 - 6,677.50 |
| Cipla Ltd. | 1,10,282.52 | 1,374.75 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,09,381.80 | 1,313.60 | 1,138.50 - 1,138.50 |
| Max Healthcare Institute Ltd. | 98,852.37 | 1,011.25 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 97,505.92 | 2,352.40 | 1,909.70 - 1,909.70 |
| Zydus Lifesciences Ltd. | 94,495.43 | 941.70 | 835.50 - 835.50 |
No Records Found
Latest News
Sanofi India informs about press release
In accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sanofi India has informed that it enclosed press release titled 'Sanofi India Limited appoints Mr. Rahul Bhatnagar as the Chairman of its Board of Directors’.
The above information is a part of company’s filings submitted to BSE.
Sanofi India informs about board meeting
Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sanofi India has informed that the meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, 28th April 2026, to consider and approve the Unaudited Financial Results for the quarter ended 31st March 2026. Further, in reference to intimation dated 24th March 2026 for closure of trading window, the trading window for the purpose of publication of Unaudited Financial Results of the Company for the quarter ended 31st March 2026 shall remain closed from Wednesday, 1st April 2026 till to Thursday, 30th April 2026.
The above information is a part of company’s filings submitted to BSE.
Sanofi India informs about investor meet outcome
Sanofi India has informed that the Audio-Video recording of the Investors/Analysts Call held on 26th February 2026 at 4:00pm for discussion on Financial Results for the quarter and year ended 31st December 2025 has been uploaded on the website of the Company.
The above information is a part of company’s filings submitted to BSE.
Sanofi India informs about disclosure
Venmax Drugs and Pharmaceuticals informs about board meeting
In terms of Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Venmax Drugs and Pharmaceuticals has informed that the Meeting of the Board of Directors is scheduled to be held on Thursday, May 14, 2026 at 3.30 pm to consider and approve, the Audited Financial Results of the Company for the Quarter and Year ended March 31, 2026. Further, the Trading Window for dealing in Securities of the Company which stands closed for all the Designated Persons of the Company with effect from April 1, 2026 would continue to remain closed till May 16, 2026 i.e., till 48 hours after the approval of the Audited Standalone Financial Results of the Company for the Quarter and Year ended March 31, 2026.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Sanofi India Ltd. is ₹3,435.50 as of 2026-05-07.
The market capitalisation of Sanofi India Ltd. is ₹7,823.39 as of 2026-05-06.
The 1-year return of Sanofi India Ltd. is 36.80% as of 2026-05-07.
The P/E ratio of Sanofi India Ltd. is 28.81 as of 2026-05-07.
The 52-week high and low of Sanofi India Ltd. are ₹6,410.00 and ₹3,160.00, respectively, as of 2026-05-07.
Disclaimer
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
